Copyright is owned by the Author of the thesis. Permission is given for a copy to be downloaded by an individual for the purpose of research and private study only. The thesis may not be reproduced elsewhere without the permission of the Author.
A critical analysis of New Zealand’s *Psychoactive Substances Act* 2013 and its implementation process

A thesis presented in partial fulfilment of the requirements for the degree of

Doctor of Philosophy

In

Public Health

at Massey University, Albany, New Zealand.

Marta Rychert

2017
Abstract

Introduction: In July 2013, the New Zealand Parliament passed the *Psychoactive Substances Act* (PSA), the world’s first law to regulate the availability of new psychoactive substances (NPS, “legal highs”, LH). Under the “interim PSA regime” 47 products were permitted to be sold subject to new retail and other regulations. In May 2014, the Government abruptly ended the interim regime following public protests. This thesis aims to critically evaluate the PSA and its implementation.

Methods: A mixed methods approach combined qualitative and quantitative methods of data collection and analysis. Legal analysis of the PSA and related legislation, and content analysis of parliamentary debates and public submissions were completed. Semi-structured interviews were then conducted with key informants (KI) including politicians, government officials, health professionals, and LH industry actors (n=30). Questions about health perceptions and social acceptability of approved products were added to an annual survey of police arrestees (n=834). Analyses of primary data included thematic analysis of interview transcripts and statistical analysis of data from the arrestee survey.

Results: The legal definition of “psychoactive substance” (s. 8, 9(1) PSA) overlaps with other regulatory regimes (e.g. medicines, dietary supplements) resulting in an unclear legal status for some products. Interviewed KIs identified a number of issues with the “interim regime”, including the safety of interim products, speed and efficiency of withdrawing problem products, the lack of regulations on price and retail opening hours, slowness of developing regulations for the full PSA regime, and the effectiveness of communicating the new policy to stakeholders and the public. As the market commercialised, the LH industry adopted business and lobbying strategies previously attributed to the alcohol and tobacco sectors, including targeting vulnerable customers. Surveyed police arrestees considered approved synthetic cannabis (SC) products higher health risk and less socially acceptable than alcohol, tobacco and many illegal drugs, reflecting problems with interim product approvals. The ban on animal testing of prospective products is likely to prevent further implementation of the PSA, unless a new political consensus is achieved.

Conclusions: The issues experienced during PSA implementation highlight the significant challenges of establishing a legal market for psychoactive products. The time, resources and planning required to successfully implement the PSA may have been underestimated.
Personal statement

I studied law in Warsaw (Poland) and Lisbon (Portugal), and graduated with a Master’s Degree in Law from the University of Warsaw in April 2013. I also worked as a journalist for a couple of years, including as an individual contractor with the Ministry of Justice in Poland. I completed formal education in media studies, obtaining a bachelor’s degree from the National School of Film, Television and Theatre in Łódź (Poland) in September 2011. This varied educational and professional background gives me a unique approach to studying laws, with a particular interest in “law in action”, where the focus is on how law works in the real world and how it is applied in society rather than purely how it stands in statutes.

I developed my interest in laws controlling access to illegal drugs during a three-month study visit at the Centre for Legal and Economic Research, University of Porto (Portugal) in 2012. Since then my interest in the field has evolved.

I am originally from Poland, a country in Central Europe particularly hard hit by the problem of new psychoactive substances (NPS), with mass poisoning reported in 2010 and 2015. A “blanket ban” on supply of NPS products implemented in Poland in 2010 has not proved to be a long-term solution to the NPS problem. This raised my interest in alternative legal approaches to the NPS problem. During the 10 months of my internship with the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) in 2013, my interest in the issue of controlling NPS developed further.

It was June 2013, at the 3rd International Multidisciplinary Forum on New Drugs (Lisbon, Portugal), that I first learnt about New Zealand’s regulated market approach to new psychoactive substances from a presentation by Associate Professor Chris Wilkins. In March 2014 I applied for a PhD scholarship to study how the New Zealand’s market for NPS established under the Psychoactive Substances Act (PSA) 2013 worked in practice.

By the time my PhD study began in June 2014 the interim regulated market established under the PSA had been ended. This unforeseen change in the regulatory environment necessitated substantial changes in the initial PhD research proposal. However, it also raised a new set of questions about what issues and challenges with the PSA had resulted in the abrupt ending of the interim regime. My PhD aimed to investigate and analyse these issues and challenges with the intention of enhancing any future implementation of the PSA and identifying learnings for proposed regulatory regimes for other psychoactive substances.
Acknowledgements

Associate Professor Chris Wilkins and Professor Karen Witten supervised this Thesis and I would like to acknowledge their advice and guidance. In particular, I would like to thank my primary supervisor Associate Professor Chris Wilkins for his comments on drafts of research articles included in this thesis and continuous support in my research, publishing and learning process.

I would like to acknowledge the supportive research environment provided by the SHORE and Whāriki Research Centre and the administrative and editing help from SHORE staff Jan Sheeran and Lisa Morice.

This study would not be possible without participants who agreed to share their experiences about implementation of the Psychoactive Substances Act 2013. I am grateful to all study participants, who I cannot acknowledge here by name due to confidentiality reasons. Also, I would like to thank staff from the Ministry of Health for their help with the legislation and feedback provided. Anonymous reviewers of journal articles published during this PhD also provided valuable comments on the manuscripts.

I would like to thank my family for their support and encouragement.
About dissertation “by publications”

This thesis has been prepared by joining together six journal articles published or submitted for publication during the course of the PhD candidature. It is a “PhD by publication”, where each results chapter constitutes a research article with a structure typical for peer-reviewed journals. It has been written in line with Massey University Guidelines on PhD Thesis by Publication (Massey University, no date).

The thesis works as an integrated whole, with Chapters 1, 2 and 3 outlining the research context and methodology and Chapter 10 synthesising and discussing findings from all published papers. The results chapters (Chapters 4–9) constitute published research papers.

The table below contains information about publications comprising the results chapters of this thesis, and other research outputs published during this PhD. As the author of this PhD thesis, I hold primary authorship of all research papers, with my thesis supervisors and SHORE & Whāriki Research Centre support staff who contributed significantly to the research listed as co-authors. Appendix A contains a detailed statement of contribution to each research paper and other outputs published during this PhD. I have received permission from all copyright holders to reprint journal articles and other outputs in this thesis.

<table>
<thead>
<tr>
<th>PhD content</th>
<th>Article title and journal, or full reference (if published)</th>
<th>Publication status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chapter 4</td>
<td>Rychert, M., &amp; Wilkins, C. (2016). What products are considered psychoactive under New Zealand’s legal market for new psychoactive substances (NPS, ‘legal highs’)? Implications for law enforcement and penalties. Drug Testing and Analysis, 8(8), 768-778. Doi: 10.1002/dta.1943</td>
<td>published</td>
</tr>
<tr>
<td>Chapter 8</td>
<td>Rychert, M., Wilkins, C., Parker, K. &amp; Witten, K. Are government-approved “legal highs” perceived to be safer and more socially acceptable than alcohol, tobacco and illegal drugs? Findings from a survey of police arrestees in New Zealand. <em>Drug and Alcohol Review</em>. Forthcoming.</td>
<td>accepted</td>
</tr>
<tr>
<td>Appendix I</td>
<td>Rychert, M., &amp; Wilkins, C. (2017), <em>New Zealand’s pre-market approval regime for ‘low risk’ new psychoactive substances (NPS, ‘legal highs’) - a regulatory alternative to prohibition</em>, in: A. Malczewski (Ed.) Monitoring drugs and drug addiction on local level. Warsaw, Poland: Information Centre for Drugs and Drug Addiction. (Published in English and Polish)</td>
<td>published</td>
</tr>
</tbody>
</table>
Table of Contents

Abstract ........................................................................................................................................ iii
Preface ........................................................................................................................................ iv
   Personal statement ................................................................................................................ iv
   Acknowledgements ................................................................................................................ v
   About dissertation “by publications” .................................................................................... vi
List of figures ............................................................................................................................ xiv
List of tables ............................................................................................................................. xiv
List of acronyms ......................................................................................................................... xv

Chapter 1: Research context ................................................................................................... 1
   1.1 The challenge of new psychoactive substances (NPS) ................................................ 1
      1.1.1 The evolution of NPS phenomenon and definitions ........................................ 2
      1.1.2 NPS market characteristics ............................................................................ 4
      1.1.3 Health risks associated with NPS use ......................................................... 7
   1.2 New policy responses to NPS .................................................................................... 10
      1.2.1 Rapid and emergency procedures ................................................................ 12
      1.2.2 Generic, analogue and neurochemical definitions ....................................... 12
      1.2.3 Application of existing administrative laws .............................................. 13
      1.2.4 “Blanket bans” on NPS supply .................................................................... 14
      1.2.5 Summary of issues with prohibiting NPS on national level ....................... 15

Chapter 2: New Zealand’s regulated market response to NPS ........................................... 17
   2.1 The early emergence of legal highs in New Zealand ............................................... 17
   2.2 Issues raised during consultation stage for the PSA ............................................. 19
      2.2.1. Issues raised in public submissions to the Psychoactive Substances Bill .... 19
         2.2.1.1 Reasons behind support and opposition to regulation of the market ....... 19
         2.2.1.2 Recommendations made in public submissions .............................. 20
      2.2.2 Issues raised in parliamentary debates ....................................................... 21
   2.3 Regulatory mechanisms under the PSA ................................................................. 23
Regulatory management and workload during the interim regime ......................... 89
Conclusions and Discussion .................................................................................. 90

Chapter 7: Legal high industry business and lobbying strategies under a legal market for new psychoactive substances (NPS, ‘legal highs’) in New Zealand ......................... 95
Abstract .................................................................................................................. 96
Introduction .......................................................................................................... 97
Historical background: the evolution of LHI in New Zealand ................................ 97
Methods ............................................................................................................... 100
Results .................................................................................................................. 102
  LHI motivations .................................................................................................. 102
  Keeping a distance from “Big Tobacco” and “Big Alcohol” ................................ 102
  Political advocacy of LHI .................................................................................. 103
  The challenge of industry growth ................................................................. 103
  Benefits and pitfalls of industry professionalization ....................................... 104
  Marketing towards youth and low-income customers .................................... 104
  The decline in product prices ......................................................................... 105
  Price control as a means to ensure a more responsible client base ............... 105
  Brand reputation for product safety ............................................................... 106
  LHI self-regulation and its effectiveness ..................................................... 106
  The impact of the global legal high market .................................................. 107
Discussion and conclusions .................................................................................. 108

Chapter 8: Are government-approved products containing new psychoactive substances (NPS) perceived to be safer and more socially acceptable than alcohol, tobacco and illegal drugs? Findings from a survey of police arrestees in New Zealand. 113
Abstract .............................................................................................................. 114
Introduction ....................................................................................................... 115
Methods .............................................................................................................. 117
Measures ........................................................................................................... 118
Analysis .............................................................................................................. 118
Results ................................................................................................................ 119
  Demographics ................................................................................................ 119
  Perceived health risk and social acceptability of approved legal SC and approved legal PP compared to other drugs .................................................. 120
  Associations between drug use, sociodemographic characteristics and health and social acceptability score ................................................................. 121
Chapter 9: The challenge of a ban on animal testing for the development of a regulated legal market for new psychoactive substances (NPS) ('legal highs') in New Zealand: Issues and options for resolution

Abstract

Introduction

Political background: evolution of the animal testing provisions under the new regime

Methods

Results

Scenario 1: Animal testing ban is revoked or modified

Scenario 2: Wait for scientific progress on non-animal tests

Scenario 3: Applicants use non-validated in vitro test methods

Scenario 4: Unsuccessful applicants challenge rejected applications in court

Scenario 5: ‘Creative compliance’ – human trial data is presented without animal test data

Scenario 6: Philosophical reconceptualisation of the benefits from recreational psychoactive products

Discussion and Conclusions

Chapter 10: Discussion and conclusions

10.1 Synthesis of findings

10.1.1. Identified challenges with implementing the PSA during the “interim regime”

10.1.2. Critique of the PSA policy process

10.1.3. Critique of the PSA legislation

10.1.4 Social perceptions of the regulated market approach to NPS

10.2 Research implications

10.2.1 Comparison of the PSA and cannabis law reforms in Colorado, Washington and Uruguay

10.2.2 Lessons for other jurisdictions wanting to establish legal markets for recreational drugs (including cannabis)

10.2.3 Recommendations for the future implementation of the PSA in New Zealand

10.3 Research strengths and limitations
List of figures

Figure 1: Number of NPS reported to the EU and UN ................................................................. 5
Figure 2: NPS groups categorised by pharmacological effect (data up to 2015), source: UNODC
EWA (2017a) .............................................................................................................................. 6
Figure 3: Framework for the review of national responses to NPS ........................................... 11
Figure 4: Framework for the review of national responses to NPS, with examples ................. 11
Figure 5: SC-related calls received by the National Poisons Centre (October 2010 – February
2016) ............................................................................................................................................ 25
Figure 6: Logic model of the Public Health Law Research (Burris et al., 2010) ....................... 35
Figure 7: Research process flowchart ...................................................................................... 44
Figure 8: Schematic representation of relationships between definitions of psychoactive
substance and other products with potential psychoactive properties ............................... 49
Figure 9: Mean health risk and social acceptability scores for all drugs ............................... 121
Figure 10: Progress in the implementation of the PSA ............................................................ 131
Figure 11: Implementation timeline of “regulated drug market” law reforms in NZ, Colorado,
Washington and Uruguay ........................................................................................................ 148

List of tables

Table 1: Support and opposition for the PSB by submitter type ............................................. 20
Table 2: Themes identified in the analysis of parliamentary readings on the PSB ................. 22
Table 3: Interim approved products withdrawn during the interim regime and products which
remained on the interim market until PSAA (by active ingredient and declared concentration).
Compiled from data archived on PSRA website. ................................................................. 26
Table 4: Objectives of the PhD and rationales for research papers ........................................ 31
Table 5: Typology of Public Health Law Studies (Burris et al., 2010) and their relevance to this
thesis ........................................................................................................................................ 38
Table 6: Categories of products or substances exempted from the PSA regime .................. 50
Table 7: Psychoactive substances which can potentially sit in multiple regulatory regimes .... 52
Table 8: Maximum penalties for offences under DSR, FA, MA, PSA and MODA ............... 57
Table 9: Demographic characteristics of police arrestee sample ......................................... 120
Table 10: Association between drug use and demographic variables and health risk and social
acceptability scores ................................................................................................................... 122
Table 11: Association between frequent SC users and other drug user groups and social
acceptability scores .................................................................................................................. 123
Table 12: Evaluation of scenarios to overcome the animal test ban impasse ........................ 137
Table 13: Comparison of selected issues in design and implementation of regulatory responses
to recreational drugs in NZ, Colorado, Washington and Uruguay ........................................ 149
## List of acronyms

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ECJ</td>
<td>European Court of Justice</td>
</tr>
<tr>
<td>EMCDDA</td>
<td>European Monitoring Centre for Drugs and Drug Addiction</td>
</tr>
<tr>
<td>EU</td>
<td>European Union</td>
</tr>
<tr>
<td>EWA</td>
<td>Early Warning Advisory (UNODC)</td>
</tr>
<tr>
<td>EWS</td>
<td>Early Warning System (EU)</td>
</tr>
<tr>
<td>IDMS</td>
<td>Illicit Drug Monitoring System (IDMS – NZ)</td>
</tr>
<tr>
<td>KI</td>
<td>Key informant</td>
</tr>
<tr>
<td>LAPP</td>
<td>Local Approved Product Policy (NZ)</td>
</tr>
<tr>
<td>LH</td>
<td>‘Legal highs’</td>
</tr>
<tr>
<td>LHI</td>
<td>‘Legal high’ industry</td>
</tr>
<tr>
<td>MODA</td>
<td>Misuse of Drugs Act (1971 – UK; 1975 – NZ)</td>
</tr>
<tr>
<td>MOH</td>
<td>Ministry of Health</td>
</tr>
<tr>
<td>NGO</td>
<td>Non-governmental organisation</td>
</tr>
<tr>
<td>NPS</td>
<td>New psychoactive substances</td>
</tr>
<tr>
<td>NZ</td>
<td>New Zealand</td>
</tr>
<tr>
<td>NZ-ADUM</td>
<td>New Zealand Arrestee Drug Use Monitoring study</td>
</tr>
<tr>
<td>NZLC</td>
<td>New Zealand Law Commission</td>
</tr>
<tr>
<td>P</td>
<td>Participant</td>
</tr>
<tr>
<td>PSAA</td>
<td>Psychoactive Substances Amendment Act (2014 - NZ)</td>
</tr>
<tr>
<td>PSB</td>
<td>Psychoactive Substances Bill (i.e. “draft” law, before vote in Parliament - NZ)</td>
</tr>
<tr>
<td>PSEAC</td>
<td>Psychoactive Substances Expert Advisory Committee (NZ)</td>
</tr>
<tr>
<td>PSRA</td>
<td>Psychoactive Substances Regulatory Authority (NZ)</td>
</tr>
<tr>
<td>RSR</td>
<td>Restricted Substances Regime (NZ)</td>
</tr>
<tr>
<td>SC</td>
<td>Synthetic cannabinoids</td>
</tr>
<tr>
<td>TCDN</td>
<td>Temporary Class Drug Notice (NZ)</td>
</tr>
<tr>
<td>TCDO</td>
<td>Temporary Class Drug Order (UK)</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Full Form</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------</td>
</tr>
<tr>
<td>UN</td>
<td>United Nations</td>
</tr>
<tr>
<td>UNODC</td>
<td>United Nations Office on Drugs and Crime</td>
</tr>
<tr>
<td>UK</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
</tbody>
</table>